Every 8-K that Exagen Inc. (XGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XGN filings page.
Exagen Inc. reported second quarter 2026 results with record total revenue of $19.9 million, up 16% from the second quarter of 2025, and increased full-year 2026 revenue guidance to $72–$75 million from $70–$73 million.
For the quarter ended June 30, 2026, revenue was $19,941 thousand with gross margin of 61.3%. Net loss narrowed to $3,196 thousand, nearly a 30% improvement from $4,439 thousand a year earlier, and adjusted EBITDA loss improved to $114 thousand, or about $0.1 million, from $1,721 thousand.
Exagen reported record AVISE CTD test volume, a trailing-twelve-month ASP of $446 per test, up $18 or 4% year over year, and ended the quarter with approximately $25 million in cash and cash equivalents. Management highlighted progress toward sustainable profitability while continuing to invest in clinical evidence, pipeline innovation and AI-powered tools that support rheumatology workflows.
Exagen Inc. reported the results of its 2026 annual meeting of stockholders held on June 9, 2026. Stockholders elected two Class I directors to three-year terms expiring at the 2029 annual meeting: Tina S. Nova, Ph.D., who received 8,094,349 votes for and 220,954 withheld, and Scott Kahn, Ph.D., who received 6,295,837 votes for and 2,019,466 withheld, with 8,663,346 broker non-votes for each.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 16,955,368 votes for, 4 against, and 23,277 abstentions. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 8,271,156 votes for, 22,870 against, 21,277 abstentions, and 8,663,346 broker non-votes.
Exagen Inc. reported first quarter 2026 results showing record revenue and higher test pricing but continued losses. Revenue rose to $17.3 million, up 12% from 2025, with gross margin at 59.0%. AVISE CTD test volume grew 10% and trailing-twelve-month average selling price increased to $444 per test.
Net loss was $4.0 million, or $0.17 per share, slightly wider than a year ago, while adjusted EBITDA loss improved to $2.2 million. The company ended the quarter with $21.5 million in cash and cash equivalents and reaffirmed full-year 2026 revenue guidance of $70–73 million.
Exagen Inc. reported that director Ana Hooker resigned from its Board of Directors, including all committee positions, effective April 17, 2026. She had served on the Audit Committee and as chair of the Nominating and Corporate Governance Committee. The company stated her resignation was not due to any disagreement regarding operations, policies, or practices.
Following her departure, the Board size was reduced from eight to seven members, and committee memberships were realigned among remaining directors.
Exagen Inc. reported strong growth but ongoing losses for the quarter and year ended December 31, 2025. Full-year revenue reached $66.6 million, up 20% from 2024, with AVISE CTD test volume growing over 11% and average selling price rising to $441 per test.
Full-year gross margin improved to 58.3%, but the company posted a net loss of $19.9 million (or $0.93 per share), wider than 2024’s loss. Adjusted EBITDA was a loss of $9.8 million, slightly better than the prior year. Exagen ended 2025 with $32.2 million in cash and cash equivalents.
Management highlighted new biomarkers, sales-force expansion, and leadership additions, and noted a strengthened balance sheet following a $20 million stock offering and a $25 million credit facility. For 2026, Exagen expects revenue between $70 million and $73 million, signaling continued topline growth despite current unprofitability.
Exagen Inc. filed a current report to share that it has issued a press release with select preliminary unaudited financial information for the three months and year ended December 31, 2025. The company explains that its financial closing procedures for this period are still in progress, so final results may differ from the preliminary figures described in the press release.
Exagen notes that its independent registered public accounting firm, BDO USA, P.C., has not audited, reviewed, compiled or applied procedures to the preliminary information and does not provide any assurance on it. The company states that the financial details under Item 2.02 are furnished rather than filed, while specific sections of the press release, including “Select Preliminary Unaudited 2025 Results,” “Cautionary Note Regarding Select Preliminary Unaudited Financial Results,” and “Forward Looking Statements,” are treated as filed under Item 8.01 and incorporated by reference.
Exagen Inc. filed a current report to note that it has released its financial results for the three and nine months ended September 30, 2025. The company issued a press release on November 4, 2025, which is attached as Exhibit 99.1 and provides the detailed figures and commentary on its results of operations and financial condition.
The report clarifies that the earnings information and the press release are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings unless specifically referenced.
Exagen Inc. (Nasdaq: XGN) filed a Form 8-K dated July 29, 2025. The filing is limited to the disclosure that, on the same date, the company released its unaudited financial results for the three- and six-month periods ended June 30, 2025.
Item 2.02 – Results of Operations and Financial Condition: The related earnings press release is furnished as Exhibit 99.1. Because the information is furnished—not filed—it is expressly excluded from Section 18 liability and is not automatically incorporated by reference into other SEC filings.
Item 9.01 – Exhibits: 99.1 (Press Release dated July 29, 2025) and 104 (Cover Page iXBRL).
No additional material events, financial metrics, or strategic updates are included in this report.